Medicare Enrolled

Dr. Roueen Rafeyan, M.D.

Addiction Medicine (Psychiatry & Neurology) Physician · Chicago, IL
Practice pattern: Clinical Cardiology — Primarily office-based clinical cardiology
Speaking/Promotional
2525 S MICHIGAN AVE, Chicago, IL 60616
3125676691
In practice since 2005 (20 years)
NPI: 1003891458 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Rafeyan from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Rafeyan? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Rafeyan

Dr. Roueen Rafeyan is an addiction medicine physician in Chicago, IL, with 20 years of NPI registration. Based on federal Medicare data, Dr. Rafeyan performed 293 Medicare services across 165 unique beneficiaries.

Between the years covered by Open Payments, Dr. Rafeyan received a total of $2,342,549 from 35 pharmaceutical and/or device companies across 3132 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in addiction medicine (psychiatry & neurology) physician. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Rafeyan is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 20 years in practice ▲ Top 38% volume in IL $2,342,549 industry payments

Medicare Practice Summary

Medicare Utilization ↗
293
Medicare services
Top 38% in IL for addiction medicine (psychiatry & neurology) physician
165
Unique beneficiaries
$62
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~15 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

Procedure Volume Avg. paid Avg. submitted
Psychotherapy and evaluation, 30 minutes
A combined session involving psychotherapy and an evaluation and management visit lasting 30 minutes.
123 $46 $100
Office visit, established patient (30-39 min)
A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition.
83 $87 $125
Office visit, established patient (20-29 min)
An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition.
62 $64 $100
Office visit, established patient (10-19 min)
An office visit for an existing patient lasting 10 to 19 minutes. The visit involves medical evaluation and management of the patient's condition.
25 $47 $75
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.

Industry Payment Transparency

Open Payments through 2024 ↗
$2,342,549
Total received (2018-2024)
Avg $334,650/year across 7 years
Top 0% in IL for addiction medicine (psychiatry & neurology) physician
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
35
Companies
3,132
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$2,214,531 (94.5%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$108,818 (4.6%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$19,200 (0.8%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$368,926
2023
$429,489
2022
$349,636
2021
$284,760
2020
$154,462
2019
$367,934
2018
$387,341

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)
$105,322
Alkermes, Inc.
$49,153
Neurocrine Biosciences, Inc.
$46,291
Teva Pharmaceuticals USA, Inc.
$45,887
Otsuka America Pharmaceutical, Inc.
$44,831
Axsome Therapeutics, Inc.
$32,698
Janssen Pharmaceuticals, Inc
$17,238
E.R. Squibb & Sons, L.L.C.
$15,789
ABBVIE INC.
$11,493
Lundbeck LLC
$132
IDORSIA PHARMACEUTICALS US INC
$30
ACADIA Pharmaceuticals Inc
$28
Takeda Pharmaceuticals U.S.A., Inc.
$21
Indivior Inc.
$14
Top 3 companies account for 54.4% of 2024 payments
All-time payments by company (2018-2024) ›
Otsuka America Pharmaceutical, Inc.
$474,374
Alkermes, Inc.
$442,111
ITI, Inc.
$246,811
Teva Pharmaceuticals USA, Inc.
$240,728
Neurocrine Biosciences, Inc.
$202,466
Sunovion Pharmaceuticals Inc.
$170,520
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)
$105,322
Janssen Pharmaceuticals, Inc
$96,136
H. Lundbeck A S
$82,186
Neurocrine BioSciences, Inc.
$76,075
Axsome Therapeutics, Inc.
$70,335
ABBVIE INC.
$34,684
Takeda Pharmaceuticals U.S.A., Inc.
$29,229
Otsuka Pharmaceutical Development & Commercialization, Inc.
$15,925
E.R. Squibb & Sons, L.L.C.
$15,789
Allergan Inc.
$13,877
AbbVie Inc.
$9,339
Vanda Pharmaceuticals Inc.
$7,354
Allergan, Inc.
$4,239
Lundbeck LLC
$1,827
USWM, LLC
$1,758
Indivior Inc.
$446
Bausch Health US, LLC
$324
Janssen Scientific Affairs, LLC
$135
IDORSIA PHARMACEUTICALS US INC
$111
Neuronetics, Inc.
$107
Supernus Pharmaceuticals, Inc.
$80
Noven Therapeutics, LLC
$65
JAZZ PHARMACEUTICALS INC.
$53
Shire North American Group Inc
$38
ACADIA Pharmaceuticals Inc
$28
Orexo US, Inc.
$21
US WorldMeds, LLC
$20
Jazz Pharmaceuticals Inc.
$19
Noven Pharmaceuticals, Inc.
$14
Top 3 companies account for 49.7% of all-time payments
Associated products mentioned in payments ›
ABILIFY ASIMTUFII · ABILIFY MAINTENA · ABILIFY MYCITE · APLENZIN · ARISTADA · AUSTEDO · Aristada 441 mg · Austedo XR · Auvelity · BRINTELLIX · CAPLYTA · COBENFY · FANAPT · Fanapt · HETLIOZ · INGREZZA · INVEGA SUSTENNA · INVEGA TRINZA · LATUDA · LYBALVI · Lucemyra · Lucemyra/Lofexidine · NEUROSTAR TMS THERAPY · NUEDEXTA · NUPLAZID · PERSERIS · QELBREE · QUVIVIQ · REXULTI · SECUADO · SPRAVATO · SUBLOCADE · SUBOXONE SUBLINGUAL FILM · SUNOSI · TRINTELLIX · Trintellix · UZEDY · VIIBRYD · VIVITROL · VRAYLAR · VYVANSE · Vivitrol · Vivitrol 380 mg · WELLBUTRIN · ZIMHI · Zubsolv
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

The majority of payments (94%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in addiction medicine (psychiatry & neurology) physician and does not inherently indicate bias, but patients may wish to be aware. Total industry engagement is in the top 0% for addiction medicine (psychiatry & neurology) physician in IL.

Looking for an addiction medicine physician in Chicago?
Compare addiction medicine physicians in the Chicago area by procedure volume, costs, and industry payment transparency.
Browse addiction medicine physicians nearby

Geographic Context

Addiction medicine physicians within 10 mi
15
Per 100K population
0.3
County median income
$81,797
Nearest hospital
INSIGHT HOSPITAL AND MEDICAL CENTER CHICAGO
0.0 mi

Data Sources

Provider Registry NPPES Weekly updates
Medicare Enrollment PECOS Monthly updates
Practice Data Medicare Util. Annual (CY lag)
Industry Payments Open Payments CY 2024
Disciplinary History — Not public N/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →

Summary

Dr. Rafeyan is a clinical cardiology specialist, with moderate Medicare volume, with speaking/promotional industry engagement in the top 0% of IL peers, with 20 years of NPI registration.

This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →

Frequently Asked Questions

Is Dr. Rafeyan experienced with psychotherapy and evaluation, 30 minutes?
Based on Medicare claims data, Dr. Rafeyan performed 123 psychotherapy and evaluation, 30 minutes services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Rafeyan receive payments from pharmaceutical companies?
Yes. Dr. Rafeyan received a total of $2,342,549 from 35 companies across 3,132 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Rafeyan's costs compare to other addiction medicine physicians in Chicago?
Dr. Rafeyan's average Medicare payment per service is $62. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Rafeyan) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →